Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $23.00.

Several equities analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Thursday, November 14th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 23,045 shares of company stock valued at $177,242. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after buying an additional 3,972 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Aura Biosciences by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after buying an additional 5,930 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Aura Biosciences during the 4th quarter worth about $50,000. Finally, Bank of America Corp DE boosted its stake in shares of Aura Biosciences by 20.5% during the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock worth $422,000 after buying an additional 8,709 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Price Performance

Shares of AURA stock opened at $7.65 on Thursday. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The firm has a market capitalization of $382.12 million, a price-to-earnings ratio of -4.42 and a beta of 0.29. The firm has a fifty day moving average of $8.02 and a 200-day moving average of $8.74.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.